Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care in vulnerable-phase heart failure management (HERMeS): a multicentre, randomised controlled trial.
Summary
In the HERMeS phase 3 trial of 506 recently discharged heart failure patients, a telemonitoring plus structured teleintervention program reduced the composite of cardiovascular death or worsening heart failure versus usual care (HR 0.35). Benefits were observed over 6 months without reported safety signals. Findings support integrating mHealth into transitional HF care.
Key Findings
- Composite of cardiovascular death or worsening heart failure reduced with mHealth vs usual care (17% vs 41%; HR 0.35, 95% CI 0.24–0.50).
- Randomized 1:1, 506 adults post HF decompensation; follow-up 24 weeks.
- No spontaneously reported harms; consistent benefit across the vulnerable phase.
Clinical Implications
Supports routine integration of telemonitoring plus structured remote follow-up in early post-discharge HF pathways to reduce cardiovascular death and decompensation.
Why It Matters
First robust RCT to demonstrate event reduction using combined telemonitoring and teleintervention during the vulnerable post-discharge phase of heart failure.
Limitations
- Open-label design could introduce behavioral or care biases
- Conducted within one country’s health system, which may affect generalizability
Future Directions
Validate across diverse healthcare systems, assess cost-effectiveness, and delineate which teleintervention components drive the effect.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized controlled, phase 3 multicenter trial with masked endpoint adjudication.
- Study Design
- OTHER